Why Adults Drop Out on the Way to Hearing Treatment: A New Review Maps Where Care Breaks Down

A scoping review of 17 studies finds that adults abandon the cochlear implant care pathway at nearly every stage, from never being referred at all to stalling just before surgery.

Hearing treatment is often discussed as a single decision: a person either chooses to address their hearing loss or does not. In reality, getting from a first hearing concern to an effective treatment involves a long chain of steps, including screening, referral, specialist assessment, candidacy evaluation, and follow-through on the recommended option.

A new review from researchers in the United Arab Emirates and the United Kingdom takes a systematic look at where that chain breaks. Focusing on adults who are potential cochlear implant candidates, typically people with more severe hearing loss, the authors map stage by stage where people disengage, delay, or quietly disappear from care.

Background: Why the Researchers Looked at This

Cochlear implants are electronic devices, placed surgically, that can restore useful hearing to adults whose hearing loss is too severe for conventional amplification. Yet they are widely considered underused: far fewer adults receive them than would likely qualify. The usual explanation is framed as patient reluctance, as if candidates simply decide against surgery.

The authors of this review suspected the picture was more complicated. In health services research, "attrition" refers to people dropping out of a care process at any point along the way, and it can happen for reasons that have little to do with an active decision, such as never being referred, losing track of appointments, or facing costs and logistics that quietly pile up.

Their goal was to reframe cochlear implant underuse as a pathway problem: to identify each stage where adults fall away, and to sort the contributing factors into those tied to patients, providers, and the health system itself.

How the Study Was Done

The team conducted a scoping review, a structured method for mapping all the available evidence on a broad question, following PRISMA-ScR guidelines. They searched four major databases (PubMed/MEDLINE, Scopus, CINAHL, and the Cochrane Library) from each database's inception through August 2025, with an update in January 2026.

They included empirical studies that reported disengagement, delay, or failure to progress at any stage of the adult cochlear implant care pathway. Seventeen studies met the criteria. The findings were then organized using a pathway framework, so that each reported instance of attrition could be pinned to a specific stage of care rather than lumped into a single dropout statistic.

What the Researchers Found

Attrition was not concentrated at one decision point. It appeared across the pathway, with evidence clustering at three stages: before referral (3 studies), between referral and assessment (4 studies), and after assessment but before surgery (10 studies).

The early losses were driven largely by the system rather than the patient. Under-referral by frontline clinicians and limited awareness of who qualifies for an implant meant many adults never entered the pathway at all. Socioeconomic barriers compounded this, filtering out candidates before a specialist ever saw them.

Later-stage attrition looked different. Among adults who had been assessed and were approaching surgery, the review found disengagement linked to logistical constraints, uncertainty about the decision, doubts about how much benefit to expect, and the cumulative burden of repeated appointments and evaluations.

The review also exposed blind spots in the research itself. No study examined the step between surgery and device activation as a distinct attrition stage, and evidence on dropout during long-term follow-up was limited. Definitions of attrition varied so much between studies that direct comparison was often impossible.

What It Means for People with Hearing Loss

The central message is that failing to get hearing treatment is rarely a single choice. It is often the sum of many small frictions: a referral that never happens, an assessment that requires travel, a stack of appointments that becomes hard to sustain alongside work and family. Understanding this matters for anyone with hearing loss, because the same frictions that stall cochlear implant candidates also delay adults with milder loss from getting any help at all.

For adults with severe hearing loss, the practical takeaway is to ask directly about cochlear implant candidacy if hearing aids no longer help, and to expect the process to involve several stages where persistence pays off. For health systems, the review suggests that fixing under-referral and reducing the number of hoops may matter as much as improving the technology itself.

Fewer Steps, Fewer Places to Drop Out

One reason this review resonates beyond cochlear implants is that the traditional hearing care pathway asks a lot of everyone, including the majority of adults whose hearing loss is mild to moderate. Each extra appointment, referral, and cost is another place to disengage. FDA-OTC hearing aids were created to shorten that path for exactly this group, letting adults with mild-to-moderate loss start treatment without a referral chain.

Panda Air reflects that design philosophy: a modern earbud-style, self-fitting OTC hearing aid that arrives ready to wear, with 16-channel processing, multi-band adaptive noise reduction, and a fast-charge case providing 60 hours of use. An optional app can run an in-ear hearing check and tune the device to your hearing profile, but the Air works out of the box without the app or the test, so there is no required setup step to stall on. A 45-day trial from the day it arrives leaves room to decide at home rather than in a clinic corridor.

The boundary matters, though: OTC devices are approved for mild-to-moderate hearing loss. The adults in this review, with loss severe enough for implant candidacy, still benefit most from the clinical pathway, which is exactly why the review's call to smooth that pathway is important.

Limitations of This Research

As a scoping review, this study maps evidence rather than pooling it statistically, so it cannot say how large each source of attrition is, only where it has been documented. The 17 included studies defined attrition inconsistently, came mostly from high-income health systems, and left key stages (notably surgery-to-activation and long-term follow-up) nearly unexamined. The authors note these gaps as priorities for future research rather than settled conclusions.

Where This Leaves Us

This review replaces the image of the reluctant patient with something more accurate and more fixable: a long pathway with leaks at every joint. People do not simply decide against hearing treatment; they are lost to it, stage by stage, through missed referrals, mounting logistics, and accumulating doubt. Naming those stages is the first step toward sealing them, whether that means better referral habits in primary care, streamlined implant evaluations, or shorter routes to treatment for those whose hearing loss does not require surgery at all.

Ayas M, Muzaffar J, AlAmadi A, AlShamsi A, Bance ML. Attrition Across the Adult Cochlear Implant Care Pathway: A Scoping Review of Stage-Specific Disengagement. Otology & Neurotology. 2026. Retrieved from PubMed. https://doi.org/10.1097/MAO.0000000000005050